Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialty pharmaceutical company with bright prospects. The company develops and sells transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient to the body evenly over months and thereby dissolve completely.
The AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and brought in around another six million euros.
Something is happening in Warngau. The company logo on the modern high-bay warehouse in the Birkerfeld industrial area, which has just been completed, is glowing. In order to meet the increasing need for production capacities, AMW has already acquired another property in the Birkerfeld industrial area. The plans for the construction of a new production building are making great strides. “In the new building we are able to triple our production capacities in the area of implants” reports the managing director of AMW Dr. Wilfried Fischer, “this marks a decisive milestone for the long-term success of AMW”.
Important measures have been taken in the past two years to put the company on a sound financial footing. In addition to the founding investors, well-known investors such as SHS, KfW, IBG, Entrepreneurship Venture Capital, BayBG and Bayern Kapital are involved in AMW. With the implementation of the 5th round of financing, the investors reaffirmed their commitment to AMW. With the additional funds, AMW is financing the growth and development of new products at the locations in Saxony-Anhalt and especially in Bavaria.
Bavaria’s Economics Minister Ilse Aigner sees the investment as another success story of the growth fund: “With the growth fund launched at Bayern Kapital last year, we are making 100 million euros of state funds available as a co-investment for private lead investors. We want to support young, innovative companies like AMW GmbH in their growth. The company has everything it takes to continue the dynamic and successful development of recent years. The financing from the growth fund opens up new perspectives for the company with the prospect of further, permanently high-quality jobs for the region. ”
The minister’s praise is particularly aimed at the recent successes on the market, because the AMW has managed to conclude long-term contracts with well-known companies from the top 20 of the pharmaceutical industry. Since the middle of the year, plasters and implants have been manufactured in large quantities for the global market at the Warngau site in three shifts. The number of employees almost doubled in 2016.
As the only manufacturer of a generic goserelin implant worldwide, we are in a very good position, ”reports Dr. Andrea Aschenbrenner, responsible for business development at AMW for six months. “The sales pipeline is well filled and we are confident that we will be able to significantly increase sales volumes with our other products in the next few years.”
This positive development is not new to Dr. Fischer. Before founding AMW, he had successfully built a comparable company with Novosis AG. The framework for another success story has been laid. Sufficient funds, a professional environment, a young and dynamic team as well as innovative products with first market success are the perfect mix for successful business development in Bavaria.